Rare and New Mutations of B-Globin in Azari Population of Iran, a Considerable Diversity.

Background: Thalassemia, as the most common single-gene genetic disorder, is related to a defect in the synthesis of one or more hemoglobin chains. More than 200 mutations have been identified in the ß-globin gene. Globally, every susceptible racial group has its own specific spectrum of the common mutations that are well-known to a particular geographic region. On the other hand, varying numbers of diverse rare mutations may occur. Materials and Methods: The subjects of the study included 2113 heterozygote or homozygote ß-thalassemia cases selected among couples who participated in the Iranian national thalassemia screening program from January 2011 to November 2019. Molecular characterization of the ß-thalassemia mutation was initially carried out by the amplification-refractory mutation system-polymerase chain reaction (ARMS-PCR) technique for common mutations, followed by sequencing, Gap PCR, and Multiple ligation-dependent probe amplification (MLPA) methods - in cases not detected by the ARMS-PCR. Results: The existence of 39 rare and new point mutations and 4 large deletions were described in our cohort. Sicilian (-13,337bp) deletion, CD36/37 (-T), and CD15 TGG>TGA were encountered more often than the others in a decreasing order, in terms of frequency. The least frequent mutations/deletions were deletion from HBD exon 1 to HBB promoter, 619 bp deletion, Deletion from up HBBP1-Exon3 HBBP1 and up HBB-0.5Kb down HBB, CAP+8 C>A, CD37 (G>A), CD6 (-A), IVSI-2 (T>C), IVSII-705 T>G, and IVSII-772 (G>A). Each occurred once. Five mutations/variants were also determined which have not been reported previously in Iran. Conclusion: According to the findings of the study, the Northwestern Iranian population displayed a wide variety of thalassemia allelic distributions. Identification of rare and new mutations in the ß-thalassemia in the national population is beneficial for screening programs, genetic counseling, and prenatal diagnosis.

Decreased brain N-acetylaspartate in Huntington's disease.

The concentration of N-acetylaspartic acid (NAA) was measured in perchloric acid extracts of postmortem brain tissue obtained from patients with Huntington's disease and from control subjects. The material in the desalted extracts was resolved on an ion exclusion column and the content of NAA was determined by subsequent fluorometric quantitation of aspartate in hydrolyzates of the resolved NAA. The concentration of NAA in the putamen from patients with Huntington's disease was less than half that of controls (2.74 vs. 6.06 mumol/g wet weight). A smaller but significant reduction was also evident in samples of cerebral cortex from Brodmann area 10 (3.99 vs. 5.29 mumol/g), while the difference in concentrations in the cerebellum was not statistically significant. Though NAA could play a direct role in Huntington's disease, it seems more likely that the changes observed reflect illness or death of neurons, and that it may be feasible to monitor the course of Huntington's disease from NAA determinations. The same tissue extracts were also examined for the presence of D-isomers of amino acids. Only traces were found in NAA, aspartate, or glutamate.

Benefits booklet gets 'fair' start.

To make its employees better aware of the value of benefits provided them, a hospital conducted a fair to introduce and explain a new booklet on employee benefits.